Issued: April 2012.
Dasatinib, nilotinib and standard-dose imatinib for the the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70) by National Institute for Health and Clinical Excellence. Published by National Institute for Health and Clinical Excellence in 2012. Publication and catalogue information, links to buy online and reader comments.